[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"6cde80ee-7854-4076-a153-49db79a1f8a8","acronym":"8951-CL-5201","url":"https://clinicaltrials.gov/study/NCT03816163","created_at":"2021-01-18T18:51:16.508Z","updated_at":"2025-02-25T17:24:01.354Z","phase":"Phase 2","brief_title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","source_id_and_acronym":"NCT03816163 - 8951-CL-5201","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 393","initiation":"Initiation: 03/15/2019","start_date":" 03/15/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-31"},{"id":"d1fb7474-3dd7-44b8-b923-5fc52d65fdb6","acronym":"CLARITY-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06219941","created_at":"2024-01-23T20:21:10.317Z","updated_at":"2024-07-02T16:34:26.279Z","phase":"Phase 2","brief_title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","source_id_and_acronym":"NCT06219941 - CLARITY-PanTumor01","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 01/19/2027","study_completion_date":" 01/19/2027","last_update_posted":"2024-06-13"},{"id":"60729fe2-47ea-41ef-9371-7af88e4f8d8f","acronym":"Spotlight","url":"https://clinicaltrials.gov/study/NCT03504397","created_at":"2021-01-18T17:15:08.157Z","updated_at":"2024-07-02T16:34:27.058Z","phase":"Phase 3","brief_title":"A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT03504397 - Spotlight","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 566","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 09/09/2022","primary_completion_date":" 09/09/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-11"},{"id":"3a5fd4f8-44a2-4aeb-8b07-da3801ece8f2","acronym":"CLAUDIO-01","url":"https://clinicaltrials.gov/study/NCT05525286","created_at":"2023-11-28T16:15:12.175Z","updated_at":"2024-07-02T16:35:00.868Z","phase":"Phase 1/2","brief_title":"Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05525286 - CLAUDIO-01","lead_sponsor":"SOTIO Biotech a.s.","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOT102"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-27"},{"id":"3e226359-22ea-4183-8dc4-9749caa27d32","acronym":"GLOW","url":"https://clinicaltrials.gov/study/NCT03653507","created_at":"2021-01-18T17:55:46.907Z","updated_at":"2024-07-02T16:35:03.022Z","phase":"Phase 3","brief_title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT03653507 - GLOW","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 507","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-17"},{"id":"2f2a89e1-3f78-4f28-8767-c134a39deb5d","acronym":"ILUSTRO","url":"https://clinicaltrials.gov/study/NCT03505320","created_at":"2021-01-18T17:15:25.042Z","updated_at":"2024-07-02T16:35:04.695Z","phase":"Phase 2","brief_title":"A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma","source_id_and_acronym":"NCT03505320 - ILUSTRO","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-09"},{"id":"56340f92-11bf-404d-bdf4-c92c67bb6993","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001516","created_at":"2021-08-12T14:54:30.593Z","updated_at":"2024-07-02T16:35:09.043Z","phase":"Phase 1","brief_title":"Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05001516","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MSI • CLDN18","pipe":" | ","alterations":" MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive","tags":["MSI • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/29/2021","start_date":" 12/29/2021","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-04-17"},{"id":"b6dec22b-d68a-4e20-acd1-3c108bb7759f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06321913","created_at":"2024-03-22T02:47:21.968Z","updated_at":"2024-07-02T16:35:13.935Z","phase":"Phase 2","brief_title":"Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06321913","lead_sponsor":"Harbin Medical University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/15/2024","start_date":" 03/15/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"62c4f641-e07b-4061-a840-4410a2fd80ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05980416","created_at":"2023-08-08T14:08:21.220Z","updated_at":"2024-07-02T16:35:16.049Z","phase":"Phase 1","brief_title":"Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2","source_id_and_acronym":"NCT05980416","lead_sponsor":"Elevation Oncology","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-06"},{"id":"65ca8a5e-0989-42c5-b8b3-bca3de969e16","acronym":"","url":"https://clinicaltrials.gov/study/NCT05981235","created_at":"2023-08-08T14:08:32.113Z","updated_at":"2025-02-25T15:01:02.369Z","phase":"Phase 1","brief_title":"Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors","source_id_and_acronym":"NCT05981235","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD6422"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-01-01"},{"id":"c579a27c-265f-45f8-af31-1763b1f84a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164458","created_at":"2021-12-20T15:53:45.428Z","updated_at":"2024-07-02T16:35:24.966Z","phase":"Phase 1","brief_title":"Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies","source_id_and_acronym":"NCT05164458","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IBI-389"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-28"},{"id":"d373713b-7551-40ea-9bb5-fad8b89a9bc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027346","created_at":"2023-09-07T16:09:46.120Z","updated_at":"2024-07-02T16:35:37.753Z","phase":"Phase 1","brief_title":"A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT06027346","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression • CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression • CLDN18.2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/17/2023","start_date":" 07/17/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-07"},{"id":"d43594a4-8a1d-44bc-a118-39c8ae2821d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05190575","created_at":"2022-01-13T13:56:13.559Z","updated_at":"2024-07-02T16:35:41.819Z","phase":"Phase 2","brief_title":"TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT05190575","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e osemitamab (TST001)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 05/06/2023","study_completion_date":" 05/06/2023","last_update_posted":"2023-07-27"},{"id":"8b07e205-119f-4afe-8cd2-9116f0158ed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05393986","created_at":"2022-05-27T12:55:36.060Z","updated_at":"2024-07-02T16:35:46.880Z","phase":"Phase 1","brief_title":"Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors","source_id_and_acronym":"NCT05393986","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CT048"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/04/2022","start_date":" 08/04/2022","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-05-31"},{"id":"8c7009ed-e696-4413-8754-ce881c82a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT05043298","created_at":"2021-09-14T16:53:19.304Z","updated_at":"2024-07-02T16:36:03.594Z","phase":"Phase 1a/1b","brief_title":"A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05043298","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IBI360"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 03/25/2024","primary_completion_date":" 03/25/2024","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2022-09-22"},{"id":"de3ef43b-b7ce-4ca6-821c-63d13927851a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009966","created_at":"2021-08-18T15:53:40.109Z","updated_at":"2024-07-02T16:36:22.492Z","phase":"Phase 1","brief_title":"Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor","source_id_and_acronym":"NCT05009966","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-10-25"},{"id":"28293dc7-5e33-4bf9-a19c-07027b0fbda9","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT01630083","created_at":"2021-01-18T07:00:04.455Z","updated_at":"2024-07-02T16:36:51.143Z","phase":"Phase 2","brief_title":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","source_id_and_acronym":"NCT01630083 - FAST","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • epirubicin • Vyloy (zolbetuximab-clzb)"],"overall_status":"Completed","enrollment":" Enrollment 252","initiation":"Initiation: 07/19/2012","start_date":" 07/19/2012","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2020-01-18"},{"id":"c34a35a5-32f3-4d5e-8a43-5cb81135448b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01671774","created_at":"2021-03-09T08:55:20.043Z","updated_at":"2024-07-02T16:36:54.467Z","phase":"Phase 1","brief_title":"Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer","source_id_and_acronym":"NCT01671774","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 10/16/2012","start_date":" 10/16/2012","primary_txt":" Primary completion: 10/13/2014","primary_completion_date":" 10/13/2014","study_txt":" Completion: 10/13/2014","study_completion_date":" 10/13/2014","last_update_posted":"2019-10-18"},{"id":"1664127f-d902-4665-9fc2-2ed2637151b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00909025","created_at":"2021-03-09T08:53:50.437Z","updated_at":"2024-07-02T16:37:20.393Z","phase":"Phase 1","brief_title":"Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer","source_id_and_acronym":"NCT00909025","lead_sponsor":"Ganymed Pharmaceuticals GmbH","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 05/01/2010","study_completion_date":" 05/01/2010","last_update_posted":"2017-07-02"},{"id":"2e4e0216-e3d2-4227-a705-162d410a2195","acronym":"","url":"https://clinicaltrials.gov/study/NCT01197885","created_at":"2021-03-09T08:54:24.735Z","updated_at":"2024-07-02T16:37:20.403Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer","source_id_and_acronym":"NCT01197885","lead_sponsor":"Ganymed Pharmaceuticals GmbH","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2017-07-02"}]